PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

Oligodendroglioma has a relatively favorable prognosis, however, often undergoes malignant progression. We hypothesized that preclinical models of oligodendroglioma could facilitate identification of therapeutic targets in progressive oligodendroglioma. We established multiple oligodendroglioma xeno...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2019-07, Vol.25 (14), p.4375-4387
Hauptverfasser:	Tateishi, Kensuke, Nakamura, Taishi, Juratli, Tareq A, Williams, Erik A, Matsushita, Yuko, Miyake, Shigeta, Nishi, Mayuko, Miller, Julie J, Tummala, Shilpa S, Fink, Alexandria L, Lelic, Nina, Koerner, Mara V A, Miyake, Yohei, Sasame, Jo, Fujimoto, Kenji, Tanaka, Takahiro, Minamimoto, Ryogo, Matsunaga, Shigeo, Mukaihara, Shigeo, Shuto, Takashi, Taguchi, Hiroki, Udaka, Naoko, Murata, Hidetoshi, Ryo, Akihide, Yamanaka, Shoji, Curry, William T, Dias-Santagata, Dora, Yamamoto, Tetsuya, Ichimura, Koichi, Batchelor, Tracy T, Chi, Andrew S, Iafrate, A John, Wakimoto, Hiroaki, Cahill, Daniel P
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Brain Neoplasms - drug therapy Brain Neoplasms - metabolism Brain Neoplasms - pathology Cell Line, Tumor Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors Class I Phosphatidylinositol 3-Kinases - genetics Class I Phosphatidylinositol 3-Kinases - metabolism Female Humans Mice Mice, SCID Oligodendroglioma - drug therapy Oligodendroglioma - metabolism Oligodendroglioma - pathology Phosphoinositide-3 Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-akt - antagonists & inhibitors Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!